ENHANCEMENT OF CANDESARTAN CILEXETIL DISSOLUTION RATE BY USING DIFFERENT METHODS
The poor solubility and wettability of candesartan cilexetil (CAN) leads to poor dissolution and hence, low bioavailability after oral administration.
The aim of this study was to improve the dissolution rate and hence the bioavailability of CAN by preparing solid dispersions (SD)/inclusion complexes
(IC) and liquisolid (LS) systems. SD were prepared using polyethylene glycol (PEG) 6000 (hydrophilic polymer) by melting method in different drugto-
carrier ratios (1:2, 1:4 weight ratio), while IC (IC1:1 molar ratio) were made with hydroxypropyl-Î² cyclodextrin (complexing agent) by kneading
method. LS systems were prepared using PEG 400 as the nonvolatile solvent, Avicel PH102 as carrier, Aerosil 200 as the coating material. Based on the
drug release studies from SDs, SD1:4 was selected to prepare tablets, because it showed an enhanced dissolution profile in comparison with pure drug
and SD1:2 according to two-tailed Studentâ€™s t-test (p<0.05), in order to compare them with IC1:1 tablets, and LS systems and the marketed product.
Fourier transform infrared, and differential scanning calorimetry studies indicated no interaction of the drug with the carriers, and provided valuable
insight on the possible reasons for enhanced dissolution profile. Dissolution studies showed that LS systems enhanced dissolution profile of CAN
compared with SD (SD1:4) tablets, IC1:1 tablets and the marketed product. The overall rank order given for the various formulations when compared
with marketed tablets was: LS tablets > SD1:4 tablets > IC1:1 tablet > marketed tablets. Thus, the SD/IC technique and LS systems can be successfully
used for enhancement of the dissolution profile of CAN.
Keywords: Candesartan cilexetil, Liquisolid systems, Solid dispirions, Inclusion complexes.
2. Sugawara M, Kadomura S, He X, Takekuma Y, Kohri N, Miyazaki K. The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations. Eur J Pharm Sci 2005;26:1-8.
3. Youn YS, Jung JY, Oh SH, Yoo SD, Lee KC. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Release 2006;114(3):334-42.
4. Saharan VA, Choudhury PK. Dissolution enhancement of drugs. Part 1: Technologies and effect of carriers. Int J Health Res 2009;2:107-24.
5. Patil MP, Gaikwad NJ. Preparation and characterization of gliclazide-polyethylene glycol 4000 solid dispersions. Acta Pharm 2009;59(1):57â€‘65.
6. El-Badry M, Fetih G, Fathy M. Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50/13 and PEG4000. Saudi Pharm J 2009;17(3):217-25.
7. Betageri G, Makarla KR. Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques. Int J Pharm 1995;126:155-60.
8. Rawat S, Jain SK. Solubility enhancement of celecoxib using beta-cyclodextrin inclusion complexes. Eur J Pharm Biopharm 2004;57(2):263-7.
9. El-Zein H, Riad L, El-Bary AA. Enhancement of carbamazepine dissolution: In vitro and in vivo evaluation. Int J Pharm 1998;168:
10. Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2008;69(3):993-1003.
11. Tiong N, Elkordy AA. Effects of liquisolid formulations on dissolution of naproxen. Eur J Pharm Biopharm 2009;73(3):373-84.
12. Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M, Nokhodchi A. Enhancement of dissolution rate of piroxicam using liquisolid compacts. Farmaco 2005;60(4):361-5.13. ATACANDÂ® product monograph. Available from: http://www.astrazeneca.ca/documents/productprofile/ATACAND-PM.pdf. [Last accessed on 2010 May 19].
14. Sweetman SC. Martindale: The Complete Drug Reference. 36th ed., Vol. I. London: Pharmaceutical Press; 2009.
15. Spireas S, Bolton M. Liquisolid systems and methods of preparing same. U.S. Patent, 5968550; 1999.
16. Available from: http://www.accessdata.fda.gov/scripts/cder/dissolution/candesartan. [Last accessed on 2009 Mar 13].
17. Stuart B. Infrared Spectroscopy: Fundamentals and Applications. New York: Wiley; 2004.
18. Moffat AC, Osselton MD, Widdop B. Clarkeâ€™s Analysis of Drugs and Poisons. 4th ed. London: Pharmaceutical Press; 2011.
19. Matsunaga H, Eguchi T, Nishijima K, Enomoto T, Sasaoki K, Nakamura N. Solid state characterization of candesartan cilexetil (TCV-116): Crystal structure and molecular mobility. Chem Pharm Bull 1999;47(2):182-6.
20. Wen X, Tan F, Jing Z, Liu Z. Preparation and study the 1:2 inclusion complex of carvedilol with beta-cyclodextrin. J Pharm Biomed Anal 2004;34(3):517-23.
21. Naveen C, Shastri N, Tadikonda RR. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharma Sin B 2012;2(5):502-8.
22. Kamalakkannan V, Puratchikody A, Ramanathan L. Development and characterization of controlled release polar lipid microparticles of candesartan cilexetil by solid dispersion. Res Pharm Sci 2013;8:125-36.
23. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 6th ed. London: Pharmaceutical Press and American Pharmaceutical Association; 2009.
24. Shaikh SM, Avachat AM. Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions. Curr Drug Deliv 2011;8(4):346-53.
25. Sabale PM, Grampurohit ND, Gaikawad DD. Liquisolid technique for enhancement of dissolution properties of fenofibrate. Int J Pharm Sci Res 2012;3(5):1481-6.
26. Spiireas S, Sau S. Enhancement of prednisolone dissolution properties using liquisolid compacts. Int J Pharm 1998;166(2):177-88.
27. Pardhi DM, Shivhare UD, Mathur VB, Bhusari KP. Liquisolid technique for enhancement of dissolution properties of carvedilol. Dergi Pharm Lett 2010;2(5):412-27.
28. Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm 1999;181(2):143-51.
29. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997;86:1-12.
30. Fernandes CM, Teresa Vieira M, Veiga FJ. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci 2002;15(1):79-88.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.